| Pomegranate juice a stiff drink
A daily glass can act like Viagra, new research shows. Nearly half the men who drank it for a month in the American study said they found it easier to rise to the occasion. It is thought the juice is rich in antioxidants which increase blood supply to the tackle. Just like drugs for impotence, the antioxidants raise levels of nitric oxide, which relaxes blood-vessel walls. Fifty-three volunteers aged 21 to 70 – with mild to moderate problems – drank 8fl oz (235 millilitres) with their evening meal. Researcher Dr Christopher Forest, of the University of California in Los Angeles, said: "Pomegranate juice has great potential in the management of erectile dysfunction." Pomegranates have already been hailed a superfruit capable of reducing the risk of heart disease and preventing prostate cancer.
Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of ...
SEATTLE, Dec. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the Company has promoted Mark Frohlich, M.D. to the position of senior vice president of clinical affairs and chief medical officer. Dr. Frohlich, a urologic oncologist with over a decade of oncology drug development and patient treatment experience in the public and private sectors, was instrumental to the filing of the company's Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T) and has also had responsibility for monitoring the progress of the company's ongoing Phase 3 IMPACT trial (D9902B), a pivotal trial for Dendreon, the results of which could support the licensure of PROVENGE. Dr. Frohlich was promoted from the position of vice president of clinical affairs. "Mark has been an exemplary leader who has led Dendreon's clinical efforts during a very active time for the organization with the ongoing regulatory approval process of PROVENGE -- a process which Mark and the rest of our team remain committed to seeing through to the approval of this promising immunotherapy for prostate cancer," stated Mitchell H.
Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT ...
SEATTLE, Oct. 23 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the Company has completed enrollment of over 500 patients in the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The IMPACT study is a double-blind, randomized, placebo-controlled Phase 3 trial designed to measure overall survival in men with metastatic hormone-refractory prostate cancer receiving PROVENGE versus placebo. Earlier this year, following a positive recommendation from an outside panel of experts, Dendreon received a complete response letter from the U.S. Food and Drug Administration (FDA) that asked for additional evidence that would support the efficacy of PROVENGE.
|
